Replies to post #190137 on Biotech Values

[DewDiligence]

…what is to prevent TEVA from acquiring MNTA (for $50+)?

MNTA would have to divest Glatopa for such a deal to pass muster, so Teva would essentially be buying MNTA for its pipeline. While not inconceivable, such a deal seems highly unlikely as it would lower Teva’s EPS in the short run, which is something Teva has told investors it would not do.